Treatment options for postmenopausal osteoporosis.
作者信息
Walsh Garry M
机构信息
Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, United Kingdom.
出版信息
Ther Clin Risk Manag. 2012;8:367-8. doi: 10.2147/TCRM.S36280. Epub 2012 Aug 28.
Abstract
摘要
相似文献
1
Treatment options for postmenopausal osteoporosis.
Ther Clin Risk Manag. 2012;8:367-8. doi: 10.2147/TCRM.S36280. Epub 2012 Aug 28.
2
Managing osteoporosis in postmenopausal women.绝经后妇女骨质疏松症的管理。
Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 3):S9-19. doi: 10.2146/ajhp100076.
3
Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.用于预防和治疗绝经后骨质疏松症的新型选择性雌激素受体调节剂——巴多昔芬的疗效和安全性。
Curr Med Res Opin. 2010 Jul;26(7):1553-63. doi: 10.1185/03007991003795873.
4
Reasons for Not Treating Women with Postmenopausal Osteoporosis with Prescription Medications: Physicians' and Patients' Perspectives.绝经后骨质疏松症女性不使用处方药治疗的原因：医生和患者的观点。
J Womens Health (Larchmt). 2017 Dec;26(12):1302-1311. doi: 10.1089/jwh.2016.6263. Epub 2017 Oct 10.
5
Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis.巴多昔芬：第三代选择性雌激素受体调节剂在绝经后骨质疏松症管理中的不断演变的作用。
Ther Adv Musculoskelet Dis. 2012 Feb;4(1):21-34. doi: 10.1177/1759720X11422602.
6
Intravenous bisphosphonates for postmenopausal osteoporosis.用于绝经后骨质疏松症的静脉注射双膦酸盐类药物。
J Res Med Sci. 2010 May;15(3):175-84.
7
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.每月一次利塞膦酸盐：一种治疗绝经后骨质疏松症的潜在新方案。
Clin Interv Aging. 2008;3(2):227-32. doi: 10.2147/cia.s2502.
8
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.阿巴洛肽用于降低绝经后骨质疏松症妇女的非椎体和椎体骨折风险：一项网络荟萃分析。
Osteoporos Int. 2019 Jul;30(7):1465-1473. doi: 10.1007/s00198-019-04947-2. Epub 2019 Apr 6.
9
An approach to postmenopausal osteoporosis treatment: a case study review.绝经后骨质疏松症治疗方法：病例研究综述
J Am Acad Nurse Pract. 2003 Dec;15(12):539-45. doi: 10.1111/j.1745-7599.2003.tb00345.x.
10
Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.绝经后女性的骨质疏松症。针对广泛骨折风险范围的治疗选择。
Geriatrics. 2006 Jan;61(1):24-30.
本文引用的文献
1
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.长期骨质疏松症治疗：地舒单抗的安全性和疗效评估。
Ther Clin Risk Manag. 2012;8:295-306. doi: 10.2147/TCRM.S24239. Epub 2012 Jun 19.
2
Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal Japanese women with osteoporosis: a clinical practice-based observational study.阿伦膦酸钠治疗对绝经后骨质疏松日本女性跟骨超声声速（一个超声参数）的影响：一项基于临床实践的观察性研究。
Ther Clin Risk Manag. 2012;8:287-93. doi: 10.2147/TCRM.S32794. Epub 2012 Jun 20.
3
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.骨质疏松症治疗的靶向方法：地舒单抗的差异化作用机制和临床应用。
Ther Clin Risk Manag. 2012;8:253-66. doi: 10.2147/TCRM.S7688. Epub 2012 Jun 11.
4
Five-year follow-up of a woman with pregnancy and lactation-associated osteoporosis and vertebral fractures.一名妊娠和哺乳期相关骨质疏松症伴椎体骨折患者的 5 年随访。
Ther Clin Risk Manag. 2012;8:195-9. doi: 10.2147/TCRM.S30668. Epub 2012 Apr 10.
5
New understanding and treatments for osteoporosis.骨质疏松症的新认识与治疗方法。
Endocrine. 2012 Feb;41(1):58-69. doi: 10.1007/s12020-011-9570-2.
6
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.阿仑膦酸钠用于绝经后妇女骨质疏松性骨折的一级和二级预防。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD001155. doi: 10.1002/14651858.CD001155.pub2.
Zotero 插件